Salarius Pharmaceuticals, Inc. (SLRX): History, Ownership, Mission, How It Works & Makes Money

In the complex world of biopharmaceuticals, is Salarius Pharmaceuticals, Inc. (SLRX) a key player, and what makes it stand out? As of April 2025, SLRX has a market capitalization of $1.10 million. Delve into this clinical-stage company's history, ownership, and mission, and discover how it operates and generates revenue in the competitive landscape of cancer therapeutics.

With a focus on developing cancer therapies through protein inhibition and degradation, Salarius has recently reported a reduced net loss for 2024 of $5.6 million ($5.79 per share) compared to $12.5 million in 2023, alongside a merger agreement with Decoy Therapeutics, what does the future hold for this innovative company?

Explore the journey of Salarius Pharmaceuticals, from its strategic shifts and clinical trials to its planned merger, to understand its role in providing new treatment options for patients in need, considering its cash position of $2.4 million as of December 31, 2024, is expected to sustain operations through Q2 2025.

Salarius Pharmaceuticals, Inc. (SLRX) History

Salarius Pharmaceuticals Founding Timeline

Year established

The company was established in 2011.

Original location

The company was originally located in Houston, Texas.

Founding team members

The founding team included:

• David Arthur
• Dr. Angelos Stergiou, who served as the CEO

Initial capital/funding

The initial funding included a $350,000 grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Salarius Pharmaceuticals Evolution Milestones

Salarius Pharmaceuticals Transformative Moments

• Securing CPRIT Grants: Receipt of significant grants from CPRIT, totaling $12.6 million in 2012, provided crucial early-stage funding for the development of Seclidemstat.
• FDA Orphan Drug and Fast Track Designations: Obtaining Orphan Drug and Fast Track Designations from the FDA for Seclidemstat underscored the drug's potential to address unmet needs in rare cancers like Ewing sarcoma and accelerated its development pathway.
• Clinical Trial Progress: The initiation and expansion of Phase 1/2 clinical trials marked a pivotal step in evaluating the safety and efficacy of Seclidemstat, paving the way for potential regulatory approvals.
• Focus on Seclidemstat: A strategic decision to focus primarily on Seclidemstat allowed the company to concentrate resources and expertise on its most promising asset, enhancing its prospects for success.

To gain further insights into the company's guiding principles, explore Mission Statement, Vision, & Core Values of Salarius Pharmaceuticals, Inc. (SLRX).

Salarius Pharmaceuticals, Inc. (SLRX) Ownership Structure

Understanding the ownership structure of Salarius Pharmaceuticals, Inc. provides key insights into who controls the company and the distribution of stakeholder interests.

Salarius Pharmaceuticals, Inc.'s Current Status

Salarius Pharmaceuticals, Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on stock exchanges.

Salarius Pharmaceuticals, Inc.'s Ownership Breakdown

The ownership of Salarius Pharmaceuticals, Inc. is distributed among various types of shareholders. Here's a breakdown:

For more detailed insights into the ownership structure and major shareholders, check out: Exploring Salarius Pharmaceuticals, Inc. (SLRX) Investor Profile: Who’s Buying and Why?

Salarius Pharmaceuticals, Inc.'s Leadership

The leadership team at Salarius Pharmaceuticals, Inc. guides the company's strategic direction and operational execution. Key members include:

• David Arthur: Serves as the President of Salarius Pharmaceuticals.
• Daniel J. Hays: Holds the position of Chief Executive Officer.
• Cameron Durrant: Is the Chairman of the Board.

These individuals, along with other members of the executive team and board of directors, are instrumental in shaping the company's strategy and overseeing its performance.

Salarius Pharmaceuticals, Inc. (SLRX) Mission and Values

Salarius Pharmaceuticals is dedicated to developing treatments for cancers where patients need more options, particularly rare and pediatric cancers. The company focuses on translating scientific discoveries into clinical applications, aiming to improve survival rates and quality of life for patients.

Salarius Pharmaceuticals' Core Purpose

Official mission statement

While a direct, concise mission statement for Salarius Pharmaceuticals isn't explicitly available in recent sources, their core purpose can be inferred from their activities and focus:

• To develop and commercialize innovative cancer treatments, with a focus on rare and pediatric cancers.
• To translate epigenetic research into clinical applications that address unmet medical needs.
• To improve the survival rates and quality of life for cancer patients, especially those with limited treatment options.

Vision statement

Similarly, a specific vision statement isn't formally published, but the vision of Salarius Pharmaceuticals can be understood through their strategic goals and long-term objectives:

• To become a leading biopharmaceutical company in the field of epigenetic-targeted cancer therapies.
• To establish their therapies as standard-of-care treatments for select rare and pediatric cancers.
• To expand their pipeline of innovative cancer therapies through ongoing research and development efforts.

Company slogan/tagline

Currently, Salarius Pharmaceuticals does not have a widely publicized official slogan or tagline. However, considering their focus, a potential implied tagline could be:

• 'Targeting the Untreatable: Innovative Therapies for Rare Cancers.'
• 'Transforming Epigenetics into Hope for Pediatric Cancer Patients.'

For more insights into the investors and motivations behind Salarius Pharmaceuticals, explore: Exploring Salarius Pharmaceuticals, Inc. (SLRX) Investor Profile: Who’s Buying and Why?

Salarius Pharmaceuticals, Inc. (SLRX) How It Works

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing cancer therapies for patients in need. The company is committed to developing treatments for cancers that disproportionately affect children, adolescents, and patients with limited treatment options.

Salarius Pharmaceuticals, Inc.'s Product/Service Portfolio

Salarius Pharmaceuticals, Inc.'s Operational Framework

Salarius Pharmaceuticals operates with a focus on bringing innovative cancer treatments from the lab to the patients who need them. Their operational framework includes:

• Drug Development: Identifying and developing promising drug candidates like Seclidemstat.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
• Partnerships: Collaborating with research institutions and other companies to advance their drug development programs.

Salarius Pharmaceuticals, Inc.'s Strategic Advantages

Salarius Pharmaceuticals distinguishes itself through several key strategic advantages:

• Targeting High-Need Areas: Focusing on cancers with limited treatment options, potentially leading to faster regulatory pathways and market acceptance.
• Innovative Technology: Utilizing epigenetic approaches to target cancer, which can offer new ways to treat the disease.
• Experienced Management Team: A leadership team with a proven track record in drug development and commercialization.

To gain more insights into the ownership and investment aspects of Salarius Pharmaceuticals, explore: Exploring Salarius Pharmaceuticals, Inc. (SLRX) Investor Profile: Who’s Buying and Why?

Salarius Pharmaceuticals, Inc. (SLRX) How It Makes Money

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients in need. The company primarily generates revenue through strategic collaborations, licensing agreements, and potential future sales of its drug candidates, should they receive regulatory approval.

Salarius Pharmaceuticals, Inc. Revenue Breakdown

As a clinical-stage company, Salarius Pharmaceuticals' revenue streams are primarily based on collaborations and licensing agreements rather than product sales. The following is a hypothetical breakdown based on typical revenue models for similar companies:

Salarius Pharmaceuticals, Inc. Business Economics

Salarius Pharmaceuticals operates under a business model common to biotechnology firms, focusing on research, development, and clinical trials of novel therapies. Key aspects of its business economics include:

• Research and Development (R&D) Costs: A significant portion of the company's expenses is dedicated to R&D, encompassing preclinical studies, clinical trials, and drug development activities.
• Partnerships and Licensing: Strategic alliances with other pharmaceutical companies or research institutions can provide funding through upfront payments, milestone payments, and royalties on future sales.
• Intellectual Property: Patents and proprietary technology are crucial assets, providing a competitive advantage and attracting potential partners and investors.
• Regulatory Approval: Securing regulatory approval from agencies like the FDA is essential for commercializing drug candidates and generating revenue from product sales.

Salarius Pharmaceuticals, Inc. Financial Performance

As of the fiscal year 2024, Salarius Pharmaceuticals' financial performance can be characterized by the following:

• Cash Position: Maintaining a strong cash balance is vital for funding ongoing research and clinical trials. As of September 30, 2024, Salarius Pharmaceuticals reported total cash, cash equivalents and restricted cash of $15.8 million.
• Operating Expenses: The company's operating expenses primarily consist of R&D expenses and general and administrative costs. For the nine months ended September 30, 2024, research and development expenses increased to $8.5 million, compared to $7.7 million for the same period in 2023. General and administrative expenses decreased to $3.4 million for the nine months ended September 30, 2024, compared to $4.3 million for the same period in 2023.
• Net Loss: Clinical-stage biopharmaceutical companies typically experience net losses as they invest heavily in R&D without generating substantial product revenue. Salarius Pharmaceuticals' net loss for the nine months ended September 30, 2024, was approximately $10.5 million, or $1.20 per share, compared to a net loss of approximately $11.2 million, or $2.17 per share for the same period in 2023.
• Revenue: For the nine months ended September 30, 2024, Salarius Pharmaceuticals reported revenues of $1.35 million.

To gain a deeper understanding of the investors and stakeholders involved with Salarius Pharmaceuticals, explore Exploring Salarius Pharmaceuticals, Inc. (SLRX) Investor Profile: Who’s Buying and Why?

Salarius Pharmaceuticals, Inc. (SLRX) Market Position & Future Outlook

Salarius Pharmaceuticals is navigating a challenging market landscape, with its future outlook heavily dependent on the success of its clinical trials and ability to secure further funding. The company is focused on developing therapies for cancers with unmet needs, giving it a niche position, but faces competition from larger pharmaceutical companies and smaller biotech firms.

Competitive Landscape

It is difficult to accurately assess the precise market share of Salarius Pharmaceuticals (SLRX) and its competitors, as the company is in the clinical stage and does not yet have products on the market. Also, market share data is dynamic and varies across different sources and reports. However, a general overview of the competitive landscape can be provided.

Opportunities & Challenges

Industry Position

Salarius Pharmaceuticals holds a position as a clinical-stage biopharmaceutical company. Its industry standing can be further clarified by the points below:

• Niche Focus: Salarius concentrates on developing treatments for cancers with high unmet needs, specifically rare and aggressive cancers like Ewing sarcoma. This targeted approach allows them to potentially address gaps in the existing treatment landscape.
• Clinical Development: As a clinical-stage company, Salarius's value is heavily tied to the progress and outcomes of its clinical trials. Positive data can significantly enhance its standing, while setbacks can have a detrimental effect.
• Partnerships and Funding: The ability to form strategic alliances and secure funding is crucial for Salarius to advance its drug development programs. These collaborations can provide financial support, expertise, and resources necessary for navigating the complex regulatory and commercialization pathways.

To gain further insights into the investors behind Salarius Pharmaceuticals, explore this resource: Exploring Salarius Pharmaceuticals, Inc. (SLRX) Investor Profile: Who’s Buying and Why?